Sponsor

Sanofi Vaccines US Inc.

United States 1 Discovery Drive, 18370-9100, United States

About the sponsor

Research activity centers on pneumococcal immunization across infants, toddlers, children, and adolescents, with attention to immune responses against multiple serotypes and the comparative performance of 21-valent formulations.

serotype-specific immunogenicity
opsonophagocytic activity
safety and tolerability
catch-up vaccination

The portfolio includes evaluation of IgG antibody responses and functional antibody activity in pediatric age groups.

About Specializations

Sanofi Vaccines US Inc. runs clinical trials in conditions such as Pneumococcal immunisation, Immunisation, Influenza immunisation, COVID-19 immunisation, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

7 clinical trials

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Not yet recruiting

Investigational

Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years

Investigational

Czechia

Participants:18–64 years · 65+ years · Healthy volunteers
Sponsor:Sanofi Vaccines US Inc.

Contact Research Centre

Immunisation+3

Not yet recruiting

Registered drug

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug

Belgium

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
Sponsor:Sanofi Vaccines US Inc.